Prelude Capital Management, LLC Pacira Bio Sciences, Inc. Transaction History

Prelude Capital Management, LLC

  • $1.12 Billion
  • Q3 2025

A detailed history of Prelude Capital Management, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 36,535 shares of PCRX stock, worth $868,802. This represents 0.08% of its overall portfolio holdings.

Number of Shares
36,535
Previous 24,235 50.75%
Holding current value
$868,802
Previous $579,000 62.52%
% of portfolio
0.08%
Previous 0.06%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
BUY
$21.09 - $27.22 $259,407 - $334,806
12,300 Added 50.75%
36,535 $941,000
Q2 2025

Aug 14, 2025
SELL
$22.91 - $27.14 $2,382 - $2,822
-104 Reduced 0.43%
24,235 $579,000
Q1 2025

May 15, 2025
BUY
$18.33 - $27.25 $88,057 - $130,909
4,804 Added 24.59%
24,339 $604,000
Q4 2024

Feb 14, 2025
SELL
$15.3 - $20.33 $36,720 - $48,791
-2,400 Reduced 10.94%
19,535 $368,000
Q3 2024

Nov 14, 2024
BUY
$11.7 - $28.46 $29,460 - $71,662
2,518 Added 12.97%
21,935 $330,000
Q2 2024

Aug 14, 2024
BUY
$25.5 - $31.51 $124,746 - $154,146
4,892 Added 33.68%
19,417 $555,000
Q1 2024

May 15, 2024
BUY
$27.7 - $35.48 $217,195 - $278,198
7,841 Added 117.31%
14,525 $424,000
Q4 2023

Feb 14, 2024
BUY
$26.32 - $34.31 $175,922 - $229,328
6,684 New
6,684 $225,000
Q2 2023

Aug 14, 2023
BUY
$36.12 - $47.5 $252,478 - $332,025
6,990 New
6,990 $280,000
Q2 2022

Aug 15, 2022
BUY
$51.49 - $81.64 $128,261 - $203,365
2,491 Added 33.91%
9,837 $573,000
Q1 2022

May 16, 2022
SELL
$60.03 - $76.49 $268,994 - $342,751
-4,481 Reduced 37.89%
7,346 $561,000
Q4 2021

Feb 14, 2022
BUY
$47.97 - $62.21 $567,341 - $735,757
11,827 New
11,827 $712,000
Q3 2020

Nov 16, 2020
SELL
$51.97 - $63.0 $802,780 - $973,161
-15,447 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$30.8 - $52.47 $94,186 - $160,453
3,058 Added 24.68%
15,447 $811,000
Q1 2020

May 15, 2020
BUY
$28.4 - $50.7 $195,250 - $348,562
6,875 Added 124.68%
12,389 $415,000
Q4 2019

Feb 14, 2020
SELL
$36.31 - $46.83 $114,739 - $147,982
-3,160 Reduced 36.43%
5,514 $250,000
Q3 2019

Nov 14, 2019
SELL
$35.66 - $44.99 $308,565 - $389,298
-8,653 Reduced 49.94%
8,674 $330,000
Q2 2019

Aug 14, 2019
BUY
$36.57 - $47.97 $626,114 - $821,294
17,121 Added 8311.17%
17,327 $754,000
Q1 2019

May 15, 2019
BUY
$36.47 - $42.17 $7,512 - $8,687
206 New
206 $8,000

Others Institutions Holding PCRX

# of Institutions
260
Shares Held
48.9M
Call Options Held
118K
Put Options Held
63.7K
View Full List

About Pacira BioSciences, Inc.

PCRX Quotes by TradingView
  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $1.09B
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email